Tumor-derived exosome (TDE) (TDE)

Tumor-derived exosomes (TDEs) are specialized extracellular vesicles, typically 30 to 150 nanometers in diameter, that are actively secreted by malignant cells into the tumor microenvironment and systemic circulation (Kalluri & LeBleu, 2020, Science). These vesicles serve as critical mediators of intercellular communication by transporting a diverse cargo of proteins, lipids, and nucleic acids, including mRNA and miRNA, to both neighboring and distant recipient cells (Whiteside, 2016, Frontiers in Immunology). In the context of oncology, TDEs facilitate the remodeling of the extracellular matrix, promote angiogenesis, and are instrumental in the formation of pre-metastatic niches that support the colonization of distant organs (Zhang et al., 2021, Journal of Hematology & Oncology). They also play a significant role in immune evasion by delivering inhibitory signals to cytotoxic T-lymphocytes and promoting the expansion of regulatory T-cells (Whiteside, 2016). Therapeutic strategies targeting TDEs focus on inhibiting their biogenesis via neutral sphingomyelinase inhibitors like GW4869, blocking their uptake by target cells using agents like heparin, or utilizing extracorporeal filtration devices such as the Aethlon Hemopurifier to remove them from the bloodstream (Zhang et al., 2021). Despite their potential, targeting TDEs presents challenges, particularly regarding the maintenance of normal physiological exosome functions essential for healthy cell signaling.

Other names

Tumor-derived extracellular vesicleCancer-derived exosomeTEXTumor-secreted exosome

Inhibition of exosome biogenesis (e.g., via nSMase inhibition), suppression of vesicle secretion (e.g., via Rab GTPase modulation), blockade of cellular uptake (e.g., via HSPG competition), and physical removal from systemic circulation via extracorporeal filtration.